Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J C Fruchart

Showing results (11-20 of 538) with videos related to

Pageof 54
Sort By:
La Revue De Medecine Interne|January 1, 1985
[Symptomatologic value of apolipoproteins]J C Fruchart
Current Atherosclerosis Reports|December 21, 2000
Are nuclear factors the ultimate targets of drugs affecting lipid metabolism?J C Fruchart
Journal of Cardiovascular Risk|September 12, 2001
Overview. PPAR and cardiovascular riskJ C Fruchart
Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum|January 1, 1990
Lipoprotein heterogeneity and its effect on apolipoprotein assaysJ C Fruchart
Annals of Nutrition & Metabolism|April 2, 1998
Postprandial dyslipidemia: a risk factor for coronary heart diseaseJ Dallongeville, J C Fruchart
Annales De Biologie Clinique|January 1, 1973
[Lipoprotein metabolism]G Biserte, J C Fruchart
Bulletin De L'Academie Nationale De Medecine|January 1, 1991
[From cholesterol to lipoprotein particle markers and/or risk factors]J C Fruchart, J Cottet
Clinical Chemistry|June 1, 1992
Apolipoprotein A-containing lipoprotein particles: physiological role, quantification, and clinical significanceJ C Fruchart, G Ailhaud
Expert Opinion on Investigational Drugs|July 5, 2005
Post-statin approaches to hyperlipidaemiaP Duriez, J C Fruchart
Annales D'Endocrinologie|October 16, 1999
[Genes, dyslipoproteinemias and atherosclerosis: from the experimental to the therapeutic]J C Fruchart, P Duriez
Pageof 54

Showing results (11-20 of 538) with videos related to

Sort By:
Pageof 54
La Revue De Medecine Interne|January 1, 1985
[Symptomatologic value of apolipoproteins]J C Fruchart
Current Atherosclerosis Reports|December 21, 2000
Are nuclear factors the ultimate targets of drugs affecting lipid metabolism?J C Fruchart
Journal of Cardiovascular Risk|September 12, 2001
Overview. PPAR and cardiovascular riskJ C Fruchart
Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum|January 1, 1990
Lipoprotein heterogeneity and its effect on apolipoprotein assaysJ C Fruchart
Annals of Nutrition & Metabolism|April 2, 1998
Postprandial dyslipidemia: a risk factor for coronary heart diseaseJ Dallongeville, J C Fruchart
Annales De Biologie Clinique|January 1, 1973
[Lipoprotein metabolism]G Biserte, J C Fruchart
Bulletin De L'Academie Nationale De Medecine|January 1, 1991
[From cholesterol to lipoprotein particle markers and/or risk factors]J C Fruchart, J Cottet
Clinical Chemistry|June 1, 1992
Apolipoprotein A-containing lipoprotein particles: physiological role, quantification, and clinical significanceJ C Fruchart, G Ailhaud
Expert Opinion on Investigational Drugs|July 5, 2005
Post-statin approaches to hyperlipidaemiaP Duriez, J C Fruchart
Annales D'Endocrinologie|October 16, 1999
[Genes, dyslipoproteinemias and atherosclerosis: from the experimental to the therapeutic]J C Fruchart, P Duriez
Pageof 54